ELVNClinical Trials•prnewswire•
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
Sentiment:Neutral (40)
Summary
BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 25, 2025 by prnewswire